Fucoidan may treat jellyfish dermatitis by inhibiting the inflammatory effect of jellyfish venom

Aoyu Li,Yang Yue,Rongfeng Li,Chunlin Yu,Xueqin Wang,Song Liu,Ronge Xing,Pengcheng Li,Quanbin Zhang,Huahua Yu
DOI: https://doi.org/10.1016/j.ijbiomac.2023.127449
IF: 8.2
2023-10-22
International Journal of Biological Macromolecules
Abstract:Jellyfish dermatitis is a common medical problem caused by jellyfish stings. However, there are no targeted and effective medications for their treatment. Here, the biological activity of fucoidan for treatment of jellyfish dermatitis was investigated for the first time. 3 mg/mL Fucoidan attenuated the inflammatory effects of Nemopilema nomurai nematocyst venom (NnNV), including dermal toxicity and myotoxicity. Fucoidan may decrease the inflammatory effects of NnNV by downregulating MAPK and NF-κB pathways. This may be attributed to the inhibitory effect of fucoidan on metalloproteinases and phospholipase A 2 (PLA 2 ) in NnNV. 3 mg/mL fucoidan reduced the metalloproteinase activity in NnNV from 316.33 ± 20.84 U/mg to 177.33 ± 25.36 U/mg, while the inhibition of PLA 2 activity in NnNV by 1 mg/mL fucoidan could reach 37.67 ± 3.42 %. Besides, external application of 3 mg/mL fucoidan can effectively alleviate the symptoms of jellyfish dermatitis. These observations suggest that fucoidan has considerable potential for treatment of jellyfish dermatitis and could be regarded as a novel medicine for jellyfish envenomation. This study provides new ideas for treatment of jellyfish envenomation and suggests evidence for the use of fucoidan in the treatment of jellyfish dermatitis as well as broadens the potential application of fucoidan in clinical practice.
polymer science,biochemistry & molecular biology,chemistry, applied
What problem does this paper attempt to address?